18184-69-5 Usage
General Description
1-Bromo-3-(ethylsulfanyl)benzene is an organic compound with the chemical formula C8H9BrS. It is a colorless liquid that is used in the synthesis of various pharmaceuticals and agrochemicals. 1-Bromo-3-(ethylsulfanyl)benzene is known for its potential application as a building block in the production of organic molecules. It is also commonly used in organic and medicinal chemistry research as a reagent for various chemical reactions. Additionally, 1-Bromo-3-(ethylsulfanyl)benzene has potential applications in the development of new materials and polymers due to its unique chemical properties. Overall, this compound has diverse uses in the field of organic chemistry and is a versatile building block for the synthesis of various organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 18184-69-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,1,8 and 4 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 18184-69:
(7*1)+(6*8)+(5*1)+(4*8)+(3*4)+(2*6)+(1*9)=125
125 % 10 = 5
So 18184-69-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H9BrS/c1-2-10-8-5-3-4-7(9)6-8/h3-6H,2H2,1H3
18184-69-5Relevant articles and documents
THERAPEUTIC AGENTS
-
Page/Page column 45, (2008/06/13)
A compound of the formula (I): wherein R1,R2,R3, R4,Ar, A, n and m are defined herein, is disclosed as a GlyT1 inhibitor; pharmaceutical compositions containing the compound of the formula (I) are also disclosed as are their use in medicine, for example in the treatment of schizophrenia.
Structure-based design of COX-2 selectivity into flurbiprofen
Bayly, Christopher I.,Black, W. Cameron,Leger, Serge,Ouimet, Nathalie,Ouellet, Marc,Percival, M. David
, p. 307 - 312 (2007/10/03)
Comparative computer modeling of the X-ray crystal structures of cyclooxygenase isoforms COX-1 and COX-2 has led to the design of COX-2 selectivity into the nonselective inhibitor flurbiprofen. The COX-2 modeling was based on a postulated binding mode for flurbiprofen and took advantage of a small alcove in the COX-2 active site created by different positions of the Leu384 sidechain between COX-1 and COX-2. The design hypothesis was tested by synthesis and biological assay of a series of flurbiprofen analogs, culminating in the discovery of several inhibitors having up to 78-fold selectivity for COX-2 over COX-1.